New Issue: Barclays sells $15.38 million Strategic Accelerated Redemption Securities on S&P Biotech

By Sarah Lizee

Olympia, Wash., July 6 – Barclays Bank plc priced $15.38 million of 0% Strategic Accelerated Redemption Securities due July 12, 2021 linked to the S&P Biotechnology Select Industry index, according to a 424B2 filing with the Securities and Exchange Commission.

The notes will be called at par of $10 plus a premium if the index closes at or above its initial level on any quarterly observation date after six months. The premium will be 12.85% on the first date, 19.275% on the second date and 25.7% on the final one.

If the notes are not called, investors will lose 1% for every 1% that the final index level is less than the initial index level.

BofA Securities, Inc. is the agent.

Issuer:	Barclays Bank plc
Issue:	Strategic Accelerated Redemption Securities
Underlying index:	S&P Biotechnology Select Industry
Amount:	$15,382,490
Maturity:	July 12, 2021
Coupon:	0%
Price:	Par of $10
Payout at maturity:	1% loss for every 1% that final index level is less than initial index level
Call:	At par plus premium if index closes at or above initial level on any quarterly observation date after six months; premium will be 12.85% on the first date, 19.275% on the second date and 25.7% on the final one
Initial index level:	8,871.97
Pricing date:	June 25
Settlement date:	July 2
Agent:	BofA Securities, Inc.
Fees:	1.25%
Cusip:	06747H388

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.